IFP Advisors Inc Grows Stock Holdings in Gilead Sciences, Inc. $GILD

IFP Advisors Inc increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 63.0% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 10,997 shares of the biopharmaceutical company’s stock after buying an additional 4,252 shares during the period. IFP Advisors Inc’s holdings in Gilead Sciences were worth $1,225,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Swiss Life Asset Management Ltd grew its stake in shares of Gilead Sciences by 5.9% in the third quarter. Swiss Life Asset Management Ltd now owns 569,271 shares of the biopharmaceutical company’s stock worth $63,189,000 after acquiring an additional 31,807 shares during the last quarter. Groupama Asset Managment raised its position in shares of Gilead Sciences by 47.5% in the 3rd quarter. Groupama Asset Managment now owns 52,281 shares of the biopharmaceutical company’s stock worth $5,803,000 after purchasing an additional 16,848 shares during the last quarter. Investment Research Partners LLC purchased a new position in shares of Gilead Sciences in the 3rd quarter worth about $928,000. CIBC Bancorp USA Inc. bought a new position in Gilead Sciences in the 3rd quarter worth about $24,418,000. Finally, Achmea Investment Management B.V. grew its position in Gilead Sciences by 5.4% during the 3rd quarter. Achmea Investment Management B.V. now owns 480,352 shares of the biopharmaceutical company’s stock valued at $53,319,000 after purchasing an additional 24,564 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 2.8%

Shares of GILD stock opened at $137.21 on Monday. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The company has a market cap of $170.34 billion, a price-to-earnings ratio of 20.27, a PEG ratio of 1.80 and a beta of 0.36. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29. The firm has a fifty day moving average price of $142.69 and a 200-day moving average price of $127.98.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be given a $0.82 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a yield of 2.4%. The ex-dividend date is Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.45%.

Analysts Set New Price Targets

A number of research firms have weighed in on GILD. Argus raised their price objective on shares of Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Rothschild & Co Redburn boosted their price objective on shares of Gilead Sciences from $159.00 to $170.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Jefferies Financial Group began coverage on Gilead Sciences in a research report on Tuesday, March 10th. They issued a “buy” rating and a $180.00 price objective on the stock. Finally, Mizuho increased their target price on Gilead Sciences from $140.00 to $170.00 and gave the company an “outperform” rating in a research note on Wednesday, February 18th. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $157.62.

Insider Buying and Selling at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $144.79, for a total value of $1,447,900.00. Following the completion of the transaction, the chief executive officer owned 642,308 shares in the company, valued at approximately $92,999,775.32. This trade represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, March 16th. The stock was sold at an average price of $144.23, for a total transaction of $432,690.00. Following the transaction, the insider directly owned 131,779 shares of the company’s stock, valued at $19,006,485.17. The trade was a 2.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 309,280 shares of company stock worth $44,068,850 in the last ninety days. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.